Johnson & Johnson

01/07/2025 | Press release | Distributed by Public on 01/07/2025 07:05

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show statistically significant and clinically meaningful improvement in overall survival versus osimertinib